|Bid||178.00 x 1000|
|Ask||300.00 x 900|
|Day's Range||215.71 - 221.64|
|52 Week Range||95.58 - 221.64|
|Beta (5Y Monthly)||1.21|
|PE Ratio (TTM)||40.77|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||232.50|
Toshiba Corporation (TOKYO: 6502), Tohoku University Tohoku Medical Megabank Organization (ToMMo) and Tohoku University Hospital have demonstrated that quantum cryptographic communications technology can provide genomic medicine with a safe, completely secure data management environment. This was achieved by (1) developing a system which applies quantum cryptographic communications technology to clinical sequencing, and (2) using that system to safely transmit cancer genome analysis data (exome sequence (Note 1) data), via online expert panel attended by physicians and other experts to analyze the sequenced data (Figure 1). This is the world's first development and demonstration of a system using quantum cryptographic communication technology in the field of genomic medicine (Note 2).
Charles River (CRL) delivered earnings and revenue surprises of 24.41% and 7.41%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Charles River (NYSE:CRL) moved higher by 0.1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share were down 3.07% year over year to $1.58, which beat the estimate of $1.26.Revenue of $682,584,000 up by 3.80% year over year, which beat the estimate of $641,630,000.Outlook The upcoming fiscal year's EPS expected to be between $7.05 and $7.35.The upcoming fiscal year's revenue expected to be between $2,817,575,000 and $2,857,000,000.Details Of The Call Date: Aug 05, 2020View more earnings on CRLTime: 09:30 AMET Webcast URL: https://edge.media-server.com/mmc/p/4xv2t4mzRecent Stock Performance 52-week high: $208.4452-week low: $95.58Price action over last quarter: Up 27.80%Company Profile Charles River Laboratories is a leading provider of drug discovery and development services. With roughly 50% of market share worldwide, the research model and services segment is the leading provider of animal models for laboratory testing. About half of the company's revenue comes from drug discovery and preclinical testing, and one fourth comes from the manufacturing support segment.See more from Benzinga * Stocks That Hit 52-Week Highs On Monday * Stocks That Hit 52-Week Highs On Tuesday * Stocks That Hit 52-Week Highs On Wednesday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Today we will run through one way of estimating the intrinsic value of Charles River Laboratories International, Inc...
Charles River Laboratories Announces Second-Quarter 2020 Results
To build your earnings season watch list, look for stocks in or near a potential buy range ahead of their next report. One company that fits that bill is Agilent Technologies (A). It's expected to report on Aug. 18. The stock is approximately 5% above a 93.14 buy point from a first-stage flat base. Buying a stock just ahead of...
Luminex saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 89 to 92. When you're researching the best stocks to buy and watch, keep a close on eye on relative price strength. Luminex is within a buying range after clearing a 38.23 entry in a cup with handle.
The healthcare sector is expected to have benefited from solid demand for medical products and services in Q2, given the rising incidence of coronavirus cases as well as an ageing U.S. populace.
Charles River Laboratories (CRL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
|Maintains||Morgan Stanley: to Overweight||8/6/2020|
|Maintains||Citigroup: to Buy||8/6/2020|
|Upgrade||B of A Securities: Neutral to Buy||7/1/2020|
|Upgrade||UBS: Neutral to Buy||5/13/2020|
|Maintains||Deutsche Bank: to Buy||5/12/2020|
|Maintains||Morgan Stanley: to Overweight||5/8/2020|
Industry: Diagnostics & Research
Full Time Employees: 17,100
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines.